Original articleConcomitant use of statins and CYP3A4 inhibitors in administrative claims and electronic medical records databases
Section snippets
Data sources
Exposure to prescription medications was approximated using prescriptions dispensed from the PharMetrics Integrated Patient-Centric database and prescriptions written from the GEMS database. Eligible patients were aged ≥18 years and exposed to ATV, FLV, LOV, PRV, RSV, SMV, or SMV/EZE during the study period.
The PharMetrics Patient-Centric database includes longitudinal, integrated patient-level medical and pharmacy claims from 47 primarily private, as well as public (Medicare supplemental and
Results
Known CYP3A4 inhibitors, including those listed in the precautions sections of United States product labels, and potential CYP3A4 inhibitors identified,28, 29 are shown in Figure 1.
Discussion
Adverse drug reactions account for 3–7% of medical hospital admissions,30 and are the sixth leading cause of death, contributing to substantial morbidity, particularly in the elderly.31, 32 A propensity for physicians to repeatedly prescribe potentially interacting drug combinations has been shown previously. For example, records from computerized drug prescription screening systems and general practice databases have been used to demonstrate persistent and repeated co-prescribing of
Financial disclosures
Drs. Ming, Gandhi, Marotti, Miles, and Ke are employees of AstraZeneca. Dr. Davidson is an investigator for the AstraZeneca METEOR trial and is a consultant for AstraZeneca, Merck/Schering-Plough, Pfizer, and Takeda Pharmaceuticals. Dr. McKenney has provided consultancy for Abbott Laboratories, Agerion, AstraZeneca, Merck & Co, and Daiichi Sankyo.
Acknowledgment
The authors acknowledge editorial support from Carl Felton of Prime Medica, which was funded by AstraZeneca. Pia Pollack of AstraZeneca provided scientific input and reviewed the manuscript. Opinions expressed remain those of the named authors.
References (40)
- et al.
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
Lancet
(2004) - et al.
New insights into the pharmacodynamic and pharmacokinetic properties of statins
Pharmacol Ther
(1999) Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors
Am J Cardiol
(2004)- et al.
Health plan administrative databases can efficiently identify serious myopathy and rhabdomyolysis
J Clin Epidemiol
(2005) - et al.
An examination of the effect of cytochrome P450 drug interactions of hydroxymethylglutaryl-coenzyme A reductase inhibitors on health care utilization: a Canadian population-based study
Clin Ther
(2002) - et al.
The atlas of heart disease and stroke
(2004) - et al.
Incidence of coronary heart disease and lipoprotein cholesterol levelsThe Framingham Study
JAMA
(1986) - et al.
Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded?Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT)
JAMA
(1986) Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
JAMA
(2001)- et al.
European guidelines on cardiovascular disease prevention in clinical practice
Eur Heart J
(2003)